Downloaded 26 times
Uploaded byNamdeo Shinde
The pharma outlook 2015
This document summarizes information about the top 15 pharmaceutical companies in the world in 2015. It provides sales figures and rankings for the top 5 selling drugs worldwide from 2014. It also discusses how the "patent cliff" has affected drug makers as major drugs lose patent protection. Additionally, it outlines key factors for the US pharmaceutical industry's success and discusses the growing pharmaceutical industry and market in India.
More Related Content
Similar to The pharma outlook 2015
The pharma outlook 2015
- 1. THE PHARMA OUTLOOK 2015 Compiledand Delivered by, Mr. Namdeo G. Shinde Assistant Professor, Satara College of Pharmacy, Satara (MS) India 415004. 12 August 2015.
- 2. Johnson and Johnson Novartis Roche Pfizer Sanofi Merck GlaxoSmithKline Gileadsciences Teva Amgen AbbVie Eli lilly Bristol Mayers Astrazeneka, Bayer WORLD TOP 15 PHARMACEUTICAL COMPANIES
- 4. Top brands inthe world RANK BRAND NAME GENERIC NAME SALE 2014 COMPANY USE APPROVAL 1 Abilify Aripiprazole +2.23% Bristol Mayers Psychosis 2002 2 Humira adalimumab +3.86% AbbVie Crohns, Rhematoid arthritis 2002 3 Nexium Esmoprazole +0.74% Astrazeneka GI disorder 2000 4 Crestor Rosuvastatin +4.53% Astrazeneka Cholesterol 2002 5 Enbrel Etanercept +1.46% Amgen Rhematoid 1998
- 9. How Is ThePatent Cliff Affecting The Drug Industry? Pfizer's Lipitor, an anticholesterol that was the world's top selling drug for eight years, lost market protection at the end of 2011. In 2012, its sales ranking dropped to 14th, a nearly 61% decline in one year from $12.9 billion to $5.1 billion 2011 Bristol Myers and Sanofi's Plavix, a blood thinner, number 2 in sales in 2012 at $9.5 billion, dropped to number 12 the next year, to $5.2 billion.
- 11.
- 13. Coverage and paymentpolicies that value innovative medicines Strong science based regulatory system IP rights and its enforcements in US and abroad Competitive corporate tax rates Govt. & Private funding of R&D and emerging biopharmaceutical companies Favourable technology transfer environment Strong R&D workforce Favourable trade policy environment Key points for favourable business operating environment in US
- 16. Established in 1983by Dilip Shanghvi Sun Pharmaceuticals operates in more than 150 countries across the world. In the year 2014, Sun Pharmaceuticals acquired Ranbaxy Laboratories Limited and became the largest pharmaceutical company in India and the fifth largest pharmaceutical company in the world. 1968, Lupin is one of the fastest growing Growth rate more than 20%
- 17. A January 2014study, by economists Robert Shapiro and Aparna Mathur, predicted that ‘India could well become a global centre for innovative drug development and production, increase the life expectancy of its people, expand output and employment, and achieve considerable cost savings in medical care and government subsidies’ by increasing its IP protection. A stronger IP environment will certainly have a positive impact on the Indian economy and encourage Foreign Direct Investment Stronger IP rights:
- 19. As per 'PharmaVision 2020', the Government of India aims to make India a global leader in end to end drug manufacturing Manufacturing costs in India is low than US due to low installation and manufacturing costs Pharmaceutical exports from India have grown at a CAGR of 21 % over the last decade Indian vaccines are exported to 150 countries Currently, Indian drugs are exported to more than 200 countries in the world, with the US as the key market.
- 20. India is hometo 10,500 manufacturing units and over 3,000 pharma companies. Higher spending on R&D, owing to products patents have made India a major destination for generic drug manufacturing India's pharma exports stood at US$ 15 billion in 2013-14 India ranks fourth in terms of the total pharma market share in the Asia Pacific Approximately 70 % of the patients in developing countries receive Indian medicines through NGOs like The Clinton Foundation, Bill & Melinda Gates Foundation, Doctors Without Borders, the UNCTAD etc
- 21. Gujarat clocked thehighest growth rate in pharmaceuticals market at 22.4 % during November 2014. CLINICAL TRIALS Due to cost advantage India is increasingly becoming a hub for clinical trials. Due to genetically diverse population and availability of skilled doctors HEALTH INSURENCE Penetration of health insurance is expected to cover more than 650 million peoples by 2020. RSBY, JJBY ‘We want to believe that the Govt. will fulfill its promise’ “MAKE IN INDIA” ‘Make, Develop and Innovate in India’
- 24.